



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 15/75, C12P 21/02, C12N 9/42 // (C12N 1/21, C12R 1:107)		A1	(11) International Publication Number: WO 98/18905 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/DK97/00477 (22) International Filing Date: 28 October 1997 (28.10.97) (30) Priority Data: 1192/96 28 October 1996 (28.10.96) DK 1426/96 13 December 1996 (13.12.96) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): BJØRNVAD, Mads, Eskelund [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). SCHÜLEIN, Martin [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). JØRGENSEN, Per, Linå [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 06 February 1998 (06.02.1998)	
(54) Title: EXTRACELLULAR EXPRESSION OF CELLULOSE BINDING DOMAINS (CBD) USING BACILLUS			
(57) Abstract <p>A <i>Bacillus</i> host transformed with a vector comprising a DNA sequence encoding for a cellulose binding domain (CBD) and capable of expressing said sequence, the expressed polypeptide protein consisting essentially of one or more non-catalytical domains; the cellulose binding domain having a molecular weight in the range of from 4 kD to 35 kD and being obtainable from a microorganism or from a plant, preferably from a bacterium or a fungus; the <i>Bacillus</i> host e.g. being one of the species <i>Bacillus subtilis</i>, <i>Bacillus licheniformis</i>, <i>Bacillus megaterium</i>, <i>Bacillus stearothermophilus</i> and <i>Bacillus amyloliquefaciens</i>; and a <i>Bacillus</i> expression vector carrying an inserted DNA sequence encoding for a cellulose binding domain; and a method for producing a cellulose binding domain polypeptide in a <i>Bacillus</i> host cell.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

EXTRACELLULAR EXPRESSION OF CELLULOSE BINDING DOMAINS (CBD) USING BACILLUS

5 The present invention relates to a transformed *Bacillus* host capable of expressing a cellulose binding domain polypeptide, a *Bacillus* expression vector, and a method for producing a cellulose binding domain in a *Bacillus* host cell.

10 BACKGROUND OF THE INVENTION

Focus on the CBD as a functional domain has involved the synthesis of the domain as a single domain molecule.

One of the first pure CBD's was obtained as synthesized by automated solid phase synthesis (Kraulis P. et al. (1989).

15 It has been shown that CBDs can be expressed in *E.coli* as functional single domains, see e.g.: Ong E. et al. (1993), wherein it is disclosed that expression using *E.coli* results in a yield of 33 mg CBD per litre of culture fluid in the periplasma of the cells.

20 Recently, a double fungal CBD (a dimer) has also successfully been expressed in *E. coli*, see Linder M. Et al. (1996).

However, the expression of CBD's in *E. coli* is not a true extracellular expression and results in an unsatisfactory yield which is too low for industrial scale production of CBD.

25 US 5,525,195, US 5,536,655, WO 91/17244 and WO 91/10732 discloses expression in a *Bacillus* host cell of an endoglucanase enzyme which has the catalytically active domain operably linked to a cellulose binding domain.

Accordingly, it is the object of the present invention to
30 provide a method for producing CBD in a high yield, preferably by means of a conventional fermentation technique involving extracellular production of the CBD which in turn makes the use of CBD in industrial applications economically feasible.

35 SUMMARY OF THE INVENTION

The inventors have now found that it is possible to produce cellulose binding domains (CBDs) by expression in a *Bacillus* host.

Before the present invention, expression of a CBDs in *Bacillus* was highly unexpected, since, firstly, cellulose binding domains are known to contain disulfide bridges and, secondly, are potentially susceptible to degradation by proteases produced by the *Bacillus* host.

Accordingly, in its first aspect the present invention relates to a *Bacillus* host transformed with a vector comprising a DNA sequence encoding for a cellulose binding domain and capable of expressing the DNA sequence.

In a second aspect, the invention relates to a *Bacillus* expression vector which carries an inserted DNA sequence encoding for a cellulase binding domain.

Further, in its third aspect, the present invention relates to a method for producing a cellulose binding domain polypeptide in a *Bacillus* host cell, the method comprising the steps of

- growing under conditions to overproduce cellulose binding domain in a nutrient medium *Bacillus* host cells which have been transformed with an expression cassette which includes, as operably joined components,

a) a transcriptional and translational initiation regulatory region,

b) a DNA sequence encoding the cellulose binding domain polypeptide,

c) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the host, and

d) a selection marker gene for selecting transformed host cells; and

- recovering the cellulose binding domain polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

A cellulose binding domain (CBD) is a polypeptide which has high affinity for or binds to water-insoluble forms of cellulose and chitin, including crystalline forms.

CBDs are found as integral parts of large protein complexes consisting of two or more different polypeptide domains, for example in hydrolytic enzymes (hydrolases) which typically are composed of a catalytic domain containing the

active site for substrate hydrolysis, and a carbohydrate-binding domain or cellulose-binding domain (CBD) for binding to the insoluble matrix. Such enzymes can comprise more than one catalytic domain and one, two or three CBDs and optionally one or more polypeptide regions linking the CBD(s) with the catalytic domain(s), the latter regions usually being denoted a "linker". Examples of hydrolytic enzymes comprising a CBD are cellulases, xylanases, mannanases, arabinofuranosidases, acetyl esterases and chitinases. CBDs have also been found in algae, e.g. the red alga *Porphyra purpurea* as a non-hydrolytic polysaccharide-binding protein, see Peter Tomme et al. (1996). However, most of the known CBDs are from cellulases and xylanases.

In this context, the term "cellulose-binding domain" is intended to be understood as defined by Tomme et al., *op. cit.* This definition classifies more than 120 cellulose-binding domains into 10 families (I-X) which may have different functions or roles in connection with the mechanism of substrate binding. However, during the work resulting in the present invention a hitherto unknown CBD family has been found, cf. example 8 below; and it is anticipated that new family representatives and additional CBD families will appear in the future.

In the protein complex, typically a hydrolytic enzyme, a CBD is located at the N or C termini or is internal.

A monomeric CBD typically consists of more than about 30 and less than about 250 amino acid residues. For example, a CBD classified in Family I consists of 33-37 amino acid residues; a CBD classified in Family IIa consists of 95-108 amino acid residues; and a CBD classified in Family VI consists of 85-92 amino acid residues. Accordingly, the molecular weight of a monomeric CBD will typically be in the range of from about 4kD to about 40kD, and usually below about 35kD.

CBDs may be useful as a single domain polypeptide or as a dimer, a trimer, or a polymer; or as a part of a protein hybrid.

Chimeric protein hybrids

Chimeric protein hybrids are known in the art, see e.g. WO 90/00609, WO 94/24158 and WO 95/16782, and comprise a
5 cellulose binding domain (CBD) from another origin, preferably from another microbial origin, than the chimeric protein as such, which CBD exists as an integral part of the protein. Typically, the chimeric protein hybrids are enzyme hybrids, i.e. contain a catalytic domain together with the binding
10 domain.

Chimeric protein hybrids and enzyme hybrids can be prepared by transforming into a host cell a DNA construct comprising at least a fragment of DNA encoding the cellulose-binding domain (CBD) ligated, with or without a linker, to a
15 DNA sequence encoding the protein or enzyme and growing the host cell to express the fused gene. The recombinant fusion protein or enzyme hybrids may be described by the following formula:

20 CBD - MR - X

wherein CBD is the N-terminal or the C-terminal region of an amino acid sequence corresponding to at least the cellulose-binding domain; MR is the middle region (the linker), and may
25 be a bond, or a short linking group preferably of from about 2 to about 100 carbon atoms, more preferably of from 2 to 40 carbon atoms; or is preferably from about 2 to to about 100 amino acids, more preferably of from 2 to 40 amino acids; and X is an N-terminal or C-terminal region of a polypeptide encoded
30 by the DNA sequence encoding the protein or enzyme.

However, recombinant fusion protein or enzyme hybrids having an internal CBD are also contemplated.

A DNA sequence encoding a CBD from a given organism can be obtained conventionally by using PCR techniques, and, also
35 based on current knowledge, it is possible to find homologous sequences from other organisms.

It is contemplated that new CBDs can be found by cloning cellulases, xylanases or other plant cell wall degrading enzyme and measure the binding to cellulose. If the enzyme activity is

bound to Avicel under the standard conditions described below, it can be assumed that part of the gene codes for a binding domain.

Having obtained the DNA fragment coding for a CBD the DNA gene is inserted in a vector suitable for its expression in *Bacillus spp.*

For example, cellulose affinity can be measured by using 10 g of Avicel in a 500 ml buffered slurry (buffer: 0.1 sodium phosphate, pH 7.5) which is stirred slowly using a spoon and left swelling for 30 minutes at room temperature. Then the enzyme is added in a ratio of 1 part cellulose binding domain to 150 parts Avicel. This is done on ice which gives optimum binding within 5 to 10 minutes. The Avicel can then be washed and applied directly to SDS-PAGE for visualization of the bound proteins (since the use of SDS and cooking will release the bound proteins). Alternatively, the slurry is packed into a column and washed. The bound protein is eluted, either in ionized water or in a high pH buffer such as triethylamine (pH 11.2; 1% solution), where the pH eluted protein is quickly adjusted to neutral.

Several CBD's have been expressed in *E.coli*, however, none has ever been reported expressed and secreted from *Bacillus sp. E.coli* as an expression host for heterologues proteins has several advantages over *Bacillus spp.*, firstly because *E.coli* has a periplasmic space where proper folding of heterologues expressed genes are possible (for review see for example Hockney, R.C. (1994). Especially the oxidizing potential and the existence of disulfide oxidoreductases in the periplasma is necessary when expressing proteins with a functionality dependent on properly arranged disulfide bridges (Emmanuel Brun et al. (1995). Overproduction, purification and characterization of the cellulose binding domain of the *Erwinia chrysanthemi* secreted endoglucanase EGZ is disclosed in Eur. J. Biochem 231, 142-148, and Ong et al., (1993). Further examples of CBDs with disulfide bonds are: the N-terminal CBD of CelB from *Pseudomonas fluorescens subsp cellulosa* (NCIMB 10462) (see the alignment in Tomme P. et al., *op. cit.*, and the N-terminal CBD of CenA from *Cellulomonas fimi* (ATCC 484), N.R. Gilkes et al. (1991).

Furthermore, the periplasma of *E.coli* also acts as in protecting the heterologously expressed protein towards the action of proteases present in the supernatant as well as the cytoplasm.

5 It is also known that, when expressing secreted proteins with disulfide bridges in *Bacillus subtilis*, the level of expression drops significantly (van den Berg et al.(1993)).

Another problem with heterologue expression is the proteolytic degradation of the expressed protein. *Bacillus subtilis* 10 is known to express at least 7 different extracellular proteases (Eds. A.L. Sonenshein et al. (1993)).

Especially for CBDs which are highly hydrophobic proteins, the translocation of the protein when expressed in *Bacillus subtilis* could be severely hampered and even cause cell 15 death due to deleterious effects if the protein gets anchored to the cell membrane because of its hydrophobicity.

In its first aspect, the present invention relates to a *Bacillus* host transformed with a vector comprising a DNA sequence encoding for a CBD and capable of expressing the sequence. Obviously, the expressed polypeptide consists essentially of one or more non-catalytical domains, i.e. the 20 polypeptide does not comprise any catalytically active domain.

In a preferred embodiment, the expressed CBD or CBD-containing polypeptide has a molecular weight (Mw) which is 25 equal to or higher than about 4 kD. Preferably, the Mw is equal to or below about 35 kD, more preferably about 32 kD, even more preferably about 30 kD, especially about 25 kD.

The CBD may be expressed in the form of a single domain polypeptide, i.e. a polypeptide comprising one CBD. Alternatively, the CBD may be expressed in the form of a dimer or 30 trimer or even a polymer, i.e. a polypeptide or protein comprising two, three, or even more than three identical CBD "units".

The CBD can also be expressed as a part of a multidomain 35 polypeptide, the non-CBD part of such a polypeptide being for example one, two or even more domains without catalytic activity.

It is believed that almost any CBD can be expressed according to the present invention, i.e. by means of a trans-

formed *Bacillus* host. Preferably, such CBDs are expressed which are obtainable from a microorganism or a plant, more preferably from a bacterium or from a fungus.

5 Examples of CBDs from bacteria include CBDs obtainable from species belonging to one of the following genera: *Butyrivibrio*, *Cellulomonas*, *Clostridium*, *Microbispora*, *Micromonospora*, *Pseudomonas*, *Streptomyces*, *Thermomonospora*, *Bacillus*, *Caldocellum*, *Erwinia*, *Myxococcus*, *Cellvibrio*, *Thermoanaerobacterium*, and *Thermotoga*.

10 Examples of CBDs from fungi include CBDs obtainable from species belonging to one of the following genera: *Agaricus*, *Dictyostelium*, *Fusarium*, *Humicola*, *Neocallimastix*, *Neurospora*, *Limulus*, *Penicillium*, *Phanerochaete*, and *Trichoderma*.

15 Examples of CBDs obtainable from plants are CBDs from expansins.

The *Bacillus* host of the present invention is a neutralophilic, an alkalophilic, a mesophilic, or a thermophilic host.

20 Examples of hosts which are useful in the present invention are hosts from the species *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, and *Bacillus amyloliquefaciens*. However, it is contemplated that other *Bacillus* species may also be useful hosts for expression of CBDs

25 As described in further detail below, the host of the invention is transformed with a vector comprising a CBD encoding DNA sequence. Preferably, the vector is integrated into the genome of the host, more preferably it has been amplified on the genome.

In another preferred embodiment of the invention, the vector is present as an expression plasmid, preferably as a multicopy plasmid.

35 In a second aspect, the present invention relates to a *Bacillus* expression vector which carries an inserted CBD-encoding DNA sequence. Preferably, the expression cassette of the vector comprises regulatory regions from a *Bacillus* sp., more preferably are such regulatory regions endogenous to the host.

In a third aspect, the present invention relates to a method for producing a CBD polypeptide, the method comprising the steps of

- growing under conditions to overproduce cellulose binding domain in a nutrient medium *Bacillus* host cells which have been transformed with an expression cassette which includes, as operably joined components,
 - a) a transcriptional and translational initiation regulatory region,
 - 10 b) a DNA sequence encoding the cellulose binding domain polypeptide,
 - c) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the host, and
 - 15 d) a selection marker gene for selecting transformed host cells; and
- recovering the cellulose binding domain polypeptide.

In its fourth aspect, the present invention relates to a method for optimisation of CBD expression in a *Bacillus* host, the method comprising the steps of expression in the host of a CBD fused to a reporter molecule; and monitoring the concentration of expressed CBD in the supernatant of the fermented host by measuring the intrinsic property or properties of the reporter molecule.

25 In a preferred embodiment, the reporter molecule is a Green Fluorescent Protein, and the intrinsic property is fluorescence emission.

In its fifth and sixth aspect, the invention relates to a polypeptide hybriide consisting essentially of one or more cellulose binding domain(s) fused to a green fluorescent protein, and to a method of producing such a hybriide by expression in a *Bacillus* host, growth of the transformed host under conditions whereby the transformed culture is substantially free of untransformed cells; incubation of the transformed culture in a nutrient medium, whereby the hybriide is overproduced; and recovery of the hybriide.

EXPRESSION OF A CBD**Recombinant expression vectors**

5 A recombinant vector comprising a DNA construct encoding the CBD of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. This introduction of vector into the
10 host cell is often referred to as the transformed host cell. Such transformation indicates introduction of DNA into a host cell by using e.g. protoplasts, natural competent cells, transfection, conjugation, electroporation, or any equivalent method. Thus, the vector may be an autonomously replicating
15 vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome in part or in its entirety and replicated
20 together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the CBD of the invention is operably linked to additional segments required for transcription of the
25 DNA. In general, the expression vector is derived from plasmid or viral DNA, or may contain elements of both. The term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the
30 DNA sequence coding for the CBD.

The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

35 Examples of suitable promoters for use in bacterial host cells include the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* alpha-amylase gene, the *Bacillus subtilis* alkaline protease gene, or the

Bacillus pumilus xylosidase gene, or the phage Lambda P_R or P_L promoters or the *E. coli* lac, trp or tac promoters.

Alternatively, it is possible to design integration vectors such that the DNA encoding the CBD will only become

- 5 functionally expressed once it is properly integrated into the host genome, e.g. downstream from a resident promoter.

The DNA sequence encoding the CBD of the invention may also, if necessary, be operably connected to a suitable terminator.

- 10 The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

- The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host
15 cell, or a gene encoding resistance to e.g. antibiotics like kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycin, or the like, or resistance to heavy metals or herbicides.

- To direct an CBD of the present invention into the secre-
20 tory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the CBD in the correct reading frame. Secretory signal
25 sequences are commonly positioned 5' to the DNA sequence encoding the. The secretory signal sequence may be that normally associated with the CBD or may be from a gene encoding another secreted protein.

- The procedures used to ligate the DNA sequences coding
30 for the present CBD, the promoter and optionally the terminator and/or secretory signal sequence, respectively, or to assemble these sequences by suitable PCR amplification schemes, and to insert them into suitable vectors containing the information necessary for replication or integration, are well known to
35 persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

Green Fluorescent Protein (GFP) has become a widely used reporter molecule for monitoring gene expression, tracers of cell lineage and as fusion tags for proteins (Cramer et al.

(1996); Cubitt et al. (1995); International Patent Application PCT/DK96/00051).

GFP could be fused to CBD's creating a fusion protein having the cellulose binding property as well as the fluorescent properties. The expression of this fusion protein could be used to monitor the expressing of CBD's in *Bacillus* species and hereby be used to optimize expression levels of given CBD's.

EXAMPLES

MATERIALS AND METHODS

Strains:

Bacillus agaradherens NCIMB No. 40482 comprises the endoglucanase enzyme encoding DNA sequence of example 8.

E.coli: SJ2 (Diderichsen, B. et al. (1990))

Electrocompetent cells prepared and transformed using a Bio-Rad GenePulserTM as recommended by the manufacturer.

B. subtilis PL2306. This strain is the *B. subtilis* DN1885 (Diderichsen, B. et al. (1990)) disrupted in the transcriptional unit of the known *Bacillus subtilis* cellulase gene, resulting in cellulase negative cells. Furthermore the strain was disrupted in the *aprE* and *nprE* genes (*aprE*: Stahl and Ferrari (1984)) and (*nprE*: Yang et al (1984)). The disruptions were performed essentially as described in (Eds. Sonenshein et al. (1993), p.618).

B.subtilis PL2304. This strain is the *B.subtilis* DN1885 (Diderichsen, B., op. Cit.) disrupted in the transcriptional unit of the known *Bacillus subtilis* cellulase gene, resulting in cellulase negative cells. The disruption was performed essentially as described in (Eds. A.L. Sonenshein, op cit.) *B. subtilis* ToC46 (Diderichsen, B. et. al., op.cit.).

Plasmids:

pMB100, which is a derivative of pDN1528 (S.Jørgensen et al. (1991)). The plasmid is essentially the same as pDN1528, however a *SacI* sites was for cloning purposes introduced between the stop codon of the *amyL* gene and its terminator.

pDN1981 (P.L. Jørgensen et al. (1990))

Solutions/Media

TY and LB agar (as described in Ausubel, F. M. et al.,
5 1995).

SB: 32 g Tryptone, 20 g Yeast Extract, 5 g NaCl and 5 ml
1 N NaOH are mixed in sterile water to a final volume of 1 li-
ter. The solution is sterilised by autoclaving for 20 min at
121°C.

10 10% Avicel: 100 g of Avicel (FLUKA, Switzerland) is mixed
with sterile water to a final volume of 1 litre, and the 10%
Avicel is sterilised by autoclaving for 20 min at 121°C.

Stock solution of Congo red (SIGMA, USA). 1% in ionized
water.

15 Buffer: 0.1 M potassium phosphate, pH 7.5.

General molecular biology methods:

DNA manipulations and transformations were performed
using standard methods of molecular biology (Sambrook et al.
20 (1989) Molecular cloning: A laboratory manual, Cold Spring
Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al.,
1995; Harwood and Cutting, 1990).

Enzymes for DNA manipulations were used according to the
specifications of the suppliers.

25

EXAMPLES 1-3

Isolation of genomic DNA

Cellulomonas fimi ATCC484 was grown in TY at 30°C, 250
30 rpm for 24 hours, cells were harvested by centrifugation.

Clostridium stercorarium NCIMB 11754 was grown anaerobi-
cally at 60°C in specified media as recommended by The National
Collections of Industrial and Marine Bacteria Ltd. (Scotland).
Cells were havested by centrifugation.

35 *Pseudomonas fluorescens ssp cellulosa* NCIMB 10462 was
grown on TY agar plates for 24 hours at 30°C. Cells were
scraped of for isolation of genomic DNA.

From any of the mentioned species, genomic DNA was isolated as described by Pitcher et al. (1989).

Identification of Cellulose Binding Domains present in Glycosyl hydrolases.

Cellulose Binding Domains are classified in ten families according to their amino acid sequences, see Tomme et al. *op. cit.* Based on the disclosure in this review article three potentially different CBD sequences were chosen as models for expression purposes in *B. subtilis*:

From the family IIa the CBD of *Cellulomonas fimi* (ATCC 484) cellulase CenA (GenBank and SWISS-PROT Accession No. M15823) and the CBD of *Pseudomonas fluorescens* (NCIMB 10462) CelB (GenBank and SWISS-PROT Accession No. X52615) were chosen.

From the family VI the CBD-dimer of *Clostridium sterco-rarium* (NCIMB 11754) XynA (GenBank and SWISS-PROT Accession No.13325) was chosen.

The SWISS-PROT data obtained describe the position of the putative Cellulose Binding Domains, which informations were used to specifically design PCR primers to obtain the DNA fragments encoding the CBD's from the three different bacteria.

At the same time PCR primers were designed as to add extra codons corresponding to amino acids preceding the signal sequence of amyL which is used to direct the CBD's to the exterior of the *Bacillus subtilis* cell.

In vitro amplification of the CBD of *Cellulomonas fimi* (ATCC 484) cellulase CenA

Approximately 100 to 200 ng of genomic DNA was PCR amplified in PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % (w/v) gelatin) containing 200 μM of each dNTP, 1,5%DMSO (SIGMA,USA), 2.5 units of AmpliTaq polymerase (Per-kin-Elmer, Cetus, USA) and 100 pmol of each primer:

CELFIM01U,

5'- CTG CCT CAT TCT GCA GCA GCG GCG GCA AAT CTT AAT GCT CCC GGC
TGC CGC GTC GAC TAC -3'

CELFIM01D,

5'-CTG CCT CAT TGC ATG CAG AGC TCC TAC TAC ACG GTG CCC GTG CAG
GTG GTG -3'

5 Restriction sites PstI and SacI are underlined.

The PCR reactions was performed using a DNA thermal
cycler (Landgraf, Germany). One incubation at 94°C for 5 min
followed by thirty cycles of PCR performed using a cycle
profile of denaturation at 94°C for 1 min, annealing at 65°C for
10 1 min, and extension at 72 °C for 1 min. Ten-μl aliquots of the
amplification product was analyzed by electrophoresis in 1.5 %
agarose gels (NuSieve, FMC) with ReadyLoad 100bp DNA ladder
(GibcoBRL, Denmark) as a size marker.

15 In vitro amplification of the CBD of *Pseudomonas fluorescens*
(NCIMB10462) CelB

Approximately 100 to 200 ng of genomic DNA was PCR
amplified in HiFidelity™ PCR buffer (Boehringer Mannheim,
Germany) supplemented with 200 μM of each dNTP, 2.6 units of
20 HiFidelity™ Expand enzyme mix and 300 pmol of each primer:

PSUPPER,

5'-CGT CCT CAT TCT GCA GCA GCG GCG GCA AAT CTT AAT GCA GCA GTG
TGT GAA TAT CGG G -3'

25

PSLOWER,

5'-CTG CCT CAT TGC ATG CAG AGC TCC TAC TAT TGT CCA CCG CAA ATC
GCC -3'

Restriction sites PstI and SacI are underlined.

30

The PCR reactions was performed using a DNA thermal
cycler (Landgraf, Germany). One incubation at 94°C for 2 min,
30 sec at 60°C and 45 sec at 72°C followed by ten cycles of PCR
performed using a cycle profile of denaturation at 94°C for 30
sec, annealing at 60°C for 30 sec, and extension at 72°C for
35 45sec and twenty cycles of denaturation at 94°C for 30 sec, 60°C
for 30 sec and 72°C for 45 sec (at this elongation step 20 sec
are added every cycle). Ten-μl aliquots of the amplification

product was analyzed by electrophoresis in 1.5 % agarose gels (NuSieve, FMC) with ReadyLoad 100bp DNA ladder (GibcoBRL, Denmark) as a size marker.

5 **In vitro amplification of the CBD-dimer of Clostridium stercorarium (NCIMB 11754) XynA.**

Approximately 100 to 200 ng of genomic DNA was PCR amplified in HiFidelityTM PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μ M of each dNTP, 2.6 units of HiFidelityTM Expand enzyme mix, and 300 pmol of each primer:

CLOST03U,

5'- CTG CCT CAT TCT GCA GCA GCG GCG GCA AAT CTT AAT CCA ACT CCT
15 GCC CCA TCT CAA AGC -3'

CLOST03D2,

5'- CTG CCT CAT TGC ATG CAG AGC TCC TAC TAC CAG TCA ACA TTA ACA
GGA CCT GAG-3'

20 Restriction sites PstI and SacI are underlined.

The PCR reactions was performed using a DNA thermal cycler (Landgraf, Germany). One incubation at 94°C for 2 min, 30 sec at 60°C and 45 sec at 72°C followed by ten cycles of PCR performed using a cycle profile of denaturation at 94°C for 30 sec, annealing at 60C for 30 sec, and extension at 72°C for 45sec and twenty cyles of denaturation at 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec (at this elongation step 20 sec are added every cycle). Ten- μ l aliquots of the amplification product was analyzed by electrophoresis in 1.5 % agarose gels (NuSieve, FMC) with ReadyLoad 100bp DNA ladder (GibcoBRL, Denmark) as a size marker.

Cloning by polymerase chain reaction (PCR):
Subcloning of PCR fragments.

35

Forty- μ l aliquots of the PCR products generated as described above were purified using QIAquick PCR purification

kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μ l of 10mM Tris-HCl, pH 8.5. Twentyfive- μ l of the purified PCR fragment was digested with SacI and PstI, electrophoresed in 1.5% low gelling temperature agarose (SeaPlaque GTG, FMC) gels, the relevant fragments were excised from the gels, and purified using QIAquick Gel extraction Kit (Qiagen, USA) according to the manufacturer's instructions. The isolated DNA fragment was then ligated to PstI SacI digested pMB100 and the ligation mixture was used to transform *B.subtilisi* PL2306.

Identification and charaterization of positive clones.

Cells were plated on LB agar plates containing chloramphenicol (6 μ g/ml), 0,4% glucose and 10mM potassium hydrogen phosphate and incubated at 37°C over night. Next day colonies were restreaked onto fresh LBPG chloramphenicol agar plates and incubated at 37°C over night. The next day single colonies of each clone were transferred to liquid LB medium containing chloramphenicol (6 μ g/ml) and incubated overnight at 37°C with shaking at 250 rpm.

Plasmids were extracted from the liquid cultures using QIAGEN Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions, however the resuspension buffer was supplemented with 1 mg/ml of Chicken Egg White Lysozyme (SIGMA, USA) prior to lysing the cells at 37°C for 15 min. Five- μ l samples of the plasmids were digested with PstI and SacI. The digestions were checked by gelelectrophoresis on a 1.5% agarose gel (NuSieve, FMC). The appearence of a DNA fragment of the same size as seen from the PCR amplification indicated a positive clone. Three clones were selected each representing a CBD from the three different bacteria mentioned above: MB144 (expressing *C. fimi* CenA-CBD), MB203 (expressing *C.stercorarium* XynA-dimer-CBD) and MB207 (expressing *P.flourescens ssp cellulosa* CelB-CBD).

Nucleotide sequencing the cloned DNA fragment

Qiagen purified plasmid DNA was sequenced with the Taq
5 deoxy terminal cycle sequencing kit (Perkin Elmer, USA) using
the same primers as used above and using an Applied Biosystems
373A automated sequencer according to the manufacturers
instructions. Analysis of the sequence data is performed accor-
ding to Devereux et al.

10 Expression, secretion and functional analysis of the cloned CBDs

The clones MB144 (expressing *C. fimi* CenA-CBD), MB203
15 (expressing *C. stercoreum* XynA-dimer-CBD) and MB207
(expressing *P. fluorescens ssp cellulosa* CelB-CBD), where all
incubated for 20 hours in SB-medium at 37°C and 250 rpm. 1 ml of
cell-free supernatant was mixed with 200 µl of 10% Avicel. The
mixture was left for 1 hour incubation at 0°C. After this bind-
20 ing of CBD to Avicel the Avicel with CBD was spun 5 min at
5000g. The pellet was resuspended in 100 µl of SDS-page buffer,
boiled at 95°C for 5 min, spun at 5000g for 5 min and 25 µl was
loaded on a 18% Laemmli Tris-Glycine, SDS-PAGE NOVEX gel
(Novex, USA). The samples were electrophoresed in a Xcell™
25 Mini-Cell (NOVEX, USA) as recommended by the manufacturer, all
subsequent handling of gels including staining with comassie,
destaining and drying were performed as described by the manu-
facturer.

The appearance of protein bands of the expected sizes
30 (MB144 protein band approx. 12 kDa), (MB203 protein band apx.
35 kDa) and (MB207 protein band apx. 12 kDa) indicated expres-
sion in *B. subtilis* of functional CBDs.

EXAMPLE 4**5 Expression and purification of CBD-dimer cloned from
C.stercorarium**

Plasmid isolated from MB203 was used to transform another
Bacillus subtilis ToC46, thus obtaining a new CBD-dimer ex-
10 pressing clone MB206. Using this strain as the expression host
for the CBD-dimer, the clone was incubated in shakeflasks con-
taining SB media (6 ug/ml of chloramphenicol) for 20 hours, at
37°C and shaking at 250 rpm.

1400 ml of culture fluid supernatant was cooled on
15 ice bath. It was filtrated through Whatman Glass filter F and
then sterile filtrated through 0.45 micron millipore Type HVL P.

50 gram of Avicel was suspended in 0.1 M Sodium Phosphate
buffer, pH 7.5, at room temperature for 30 min. The supernatant
was removed and the Avicel slurry was cooled to 4°C. The clear
20 supernatant was mixed with the Avicel slurry at 4°C for 30 min.

The Avicel was settled for 10 min and the supernatant re-
moved. The Avicel protein complex was packed in a column and
washed with 0.1M sodium phosphate buffer, followed by buffer in-
cluding 0.5M sodium chloride. Finally, the CBD was eluted by
25 deionized water.

A total of 78 ml was eluted containing CBD. The CBD was
concentrated after addition of solid sodium chloride to a final
concentration of 0.5M on an Amicon cell with a R81P membrane
with a cut off of 8 kD.

30 The concentrated CBD solution (30 ml) had a absorbance at
280 nm of 1.2. The molar extinction coefficient of MB 206 was
42000 corresponding to a protein concentration of 0.82, result-
ing in a total of 25 mg of highly purified double CBD. Based on
SDS-PAGE, the starting material had about 0.1 mg per ml of 29
35 kD. The final purified product showed only a single band on
SDS-PAGE.

EXAMPLE 5

Characterization of a dimerized Fungal CBD, cloned and expressed in Bacillus subtilis

A CBD dimer of fungal origin is constructed by fusing the CBD encoded by the DNA sequence of *Humicola insolens* EGII with the CBD encoded by the DNA sequence of the 43 kDa from *Humicola insolens*.

The DNA sequence encoding *Humicola insolens* EGII CBD and linker is PCR amplified from the plasmid carrying the cDNA of EG II also known as CMC 3 (Dalbøge and Heldt Hansen, 1994) using primers specific for the CBD region and furthermore the antisense primer is designed so as to give the PCR fragment an overhang identical to the DNA fragment encoding the proceeding CBD, the CBD encoded by the gene of the 43 kDa endoglucanase from *H.insolens* which is described in detail in EP-B-0 531 372 and US 5,457,046. The DNA encoding this CBD is PCR amplified from genomic DNA of the *Humicola insulens* described in EP-B-0 531 372.

The two fragments are combined by SOE-PCR (Higuchi et al. (1988)) using the primers :

#22857

5'- CTG CCT CAT TCT GCA GCA GCG GCG GCA AAT CTT AAT CAG GGC GGT
GCA TGG CAG CAG-3'

and the primer

#20622

5'- CTG CCT CAT TGC ATG CAG AGC TCC TAC TAC AGG CAC TGA TGG TAC
CAG TC-3'

This PCR fragment is, as a PstI-SacI fragment, ligated to pMB100 and the ligation mixture is used to transform *Bacillus subtilis* PL2306.

The cloned DNA essentially encoding the CBD-dimer can be found in the sequence CBD-EGII-CZ (327bp):

GCAAATCTTA ATCAGGGCGG TGCATGGCAG CAGTGTGGTG GCGTTGGCTT
CTCGGGCTCT ACGTCCTGTG TGTCCGGTTA CACGTGCGTG TACTTGAACG ACTGGTA-
CAG CCAATGCCAG CCGCAGCCGA CGACGTTACG GACAACAACA ACGCCAGGGG
CAACATCGAC AACAAGGTCA GCCCCGGCTG CCACTTCAAC CACTCCGGCC
5 GGCTGCACTG CTGAGAGGTG GGCTCAGTGC GGCGGCAATG GCTGGAGCGG CTGCAC-
CACC TCGCTCGCTG GCAGCACTTG CACGAAGATT
AATGACTGGT ACCATCAGTG CCTGTAG

and the corresponding amino acid sequence (108 aa residues):

10 ANLNQGGAWQ QCGGVGFSGS TSCVSGYTCV YLNDWYSQCQ PQPTTLRTTT
TPGATSTTRS APAATSTTPA GCTAERWAQC GGNGWSGCTT CVAGSTCTKI NDWYHQCL

Expression, secretion and functionality of the CBD is
characterized as described above.

15

EXAMPLE 6

Construction of GFP-CBD fusion for CBD expression optimization.

Approximately 100 ng of plasmid DNA pMB144, plasmid is
20 isolated as described above, is PCR amplified in PCR buffer (10
mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.01 % (w/v)
gelatin) containing 200 μM of each dNTP, 1,5%DMSO (SIGMA,USA),
2.5 units of AmpliTaq polymerase (Perkin-Elmer, Cetus, USA) and
100 pmol of each primer:

25

C-Fusion1:.

5'-GTC AGT GAA TTC GCA TGC GTC CTT CTT TGT GCT TG-3'

C-Fusion2:

30 5'-CTC ATA AAG CTT ACG GTG CCC GTG CAG GTG GTG-3'

Restriction sites EcoRI and HindIII are underlined.

The PCR reactions is performed using a DNA thermal
cycler (Landgraf, Germany). One incubation at 94°C for 5 min
35 followed by thirty cycles of PCR performed using a cycle
profile of denaturation at 94°C for 1 min, annealing at 60°C for
1 min, and extension at 72°C for 1 min. Ten-μl aliquots of the
amplification product is analyzed by electrophoresis in 0.7 %

agarose gels (NuSieve, FMC) with ReadyLoad 100bp DNA ladder (GibcoBRL, Denmark) as a size marker.

The fragment is purified, digested with *EcoRI* and *HindIII*, gelpurified and ligated to vector pBR322 (Bolivar et al. (1977),
5 Gene, 2, 95-113.).

The ligation mixture is used to transform SJ2 electrocompetent *E.coli*.

Identification and characterization of positive clones.

10 The transformed cells are plated on LB agar plates containing ampicillin (200 µg/ml) and incubated at 37°C overnight. Next day colonies are rescued by restreaking these onto fresh LB-ampicillin agar plates and incubated at 37°C over
15 night. The second day single colonies of each clone are transferred to liquid LB medium containing ampicillin (200 µg/ml) and incubated overnight at 37°C with shaking at 250 rpm.

Plasmids are extracted from the liquid cultures using QIAGEN Plasmid Purification mini kit (Qiagen, USA) according to the
20 manufacturer's instructions. Five-µl samples of the plasmids are digested with *HindIII* and *EcoRI*. The digestions are checked by gel electrophoresis on a 0.7% agarose gel (NuSieve, FMC).

A derivative of GFP is cloned from the DNA construction of the mutant F64L-S65T-GFP which was constructed as described in
25 international patent application PCT/DK96/00051.

The DNA fragment encoding the F64L-S65T-GFP is cloned as a *BamHI*-*HindIII* fragment, In-frame with the CBD encoding DNA cloned in pBR322. Ligation, transformation and identification of a positive clone is done essentially as described above.

30 This fusion construction is transferred as a *EcoRI*-*BamHI* fragment from the *E.coli* vector to the vector pUB110 vector (Gryczan et al. (1978)). *Bacillus subtilis* PL2306 is transformed and positive clones are identified by their ability to fluoresce and by the existence of an Avicel binding F64L-S65T-
35 GFP CBD fusion polypeptide.

The wavelength of the light used for excitation of the F64L-S65T-GFP of this study is 488 nm, this activates the F64L-S65T-GFP to emit light at 510-530 nm.

The fluorescence of the supernatant is measured by fluorescence spectroscopy and compared with the fluorescence of the supernatant after incubation with Avicel. Furthermore, the fluorescent molecule with CBD can be visualized by binding the fusion protein to Avicel, removing excess supernatant and transferring the Avicel to cuvettes for fluorescent measuring in a fluorescence spectrometer.

By making serial dilutions of the Avicel bound or non-bound fusion protein, the expression level can be determined, thus making it possible to identify a *Bacillus* clone expressing relatively higher amounts of CBD.

EXAMPLE 7

Screening using CMC-CongoRed

Recombinant *Bacillus* clones expressing CBD's can be screened by means of the expression level of the CBD.

In order to find *Bacillus* strains optimal for expressing a given CBD, the clones of interest are incubated in a suitable medium e.g. as described above in TY and incubated at appropriate growth conditions for 24 hours. Supernatant of the clones are transferred to Agarose-CMC-CongoRed-plates with punched holes, the supernatant with the CBD are left to bind to the CMC for 5 hours at 37°C. When washed 15 min with 2% NaCl solution, the CBD activity can be seen as a clearing zone.

The plate assay can be combined as described below.

Preparation of the gel for use in CBD plate assay: 0.5% CMC and 0.7% agarose (CMC; Carboxymethylcellulose, 7LF from Hercules) (agarose; Litex HSA/HSB) are prepared by moistening the CMC and Agarose with 96% alcohol. 0.1 M potassium phosphate pH 7.5 buffer is added and the mixture is heated to 100°C until completely dissolved. The solution is left to cool at 60°C. Congo red stock solution is added to a final 5% and plates are poured, 15 ml to a petri dish with 9 cm diameter.

Sample application holes are made with a puncher.

EXAMPLE 8**Identification of a novel CBD defining a new CBD family**

5

The alkaline cellulase cloned in *Bacillus subtilis* as described below was expressed by incubating the clone for 20 hours in SB-medium at 37°C and 250 rpm. The expressed cellulase was shown to contain a CBD by its ability to specifically bind to Avicel.

10

When left for incubation for a further 20 hours the cellulase was proteolytically cleaved and two specific protein bands appeared on SDS-page one corresponding to the catalytic part of the cellulase approximate molecular weight (MW) 35 kD and the other corresponding to a proposed linker and CBD of approximate MW 8 kD.

15

The CBD was found to be the C-terminal part of the cellulase and the CBD did not match any of the previously described CBD families (Tomme et al., 1995, p. 142-161). Accordingly, this CBD is the first member of a new family.

20

Cloning of the alkaline cellulase from *Bacillus agaradherens* and expression of the alkaline endoglucanase in *Bacillus subtilis*

25

The nucleotide sequence encoding the alkaline cellulase from *Bacillus agaradherens* (Deposition No. NCIMB 40482) was cloned by PCR for introduction in an expression plasmid pDN1981.

30

PCR was performed essentially as described above on 500 ng of genomic DNA, using the following two primers containing NdeI and KpnI restriction sites for introducing the endoglucanase encoding DNA sequence to pDN1981 for expression:

35 Primer 5: (#20887)

5'-GTA GGC TCA GTC ATA TGT TAC ACA TTG AAA GGG GAG GAG AAT CAT
GAA AAA GAT AAC TAC TAT TTT TGT CG-3'

Primer 6: (#21318)

5'-GTA CCT CGC GGG TAC CAA GCG GCC GCT TAA TTG AGT GGT TCC CAC
5 GGA CCG-3'

After PCR cycling the PCR fragment was purified using QIAquick PCR column Kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 µl of 10mM Tris-HCl, pH 8.5. Digested with NdeI and KpnI purified and ligated to digested pDN1981. The ligation mixture was used to transform *B.subtilis* PL2304. Competent cells were prepared and transformed as described by Yasbin et al., (1975).

15 Isolation and test of *Bacillus subtilis* transformants.

The transformed cells were plated on LB agar plates containing 10 mg/ml Kanamycin, 0.4% glucose, 10 mM KH₂PO₄ and 0.1% AZCL HE-cellulose (Megazyme, Australia) and incubated at 37°C for 18 hours. Endoglucanase positive colonies were identified as colonies surrounded by a blue halo.

Each of the positive transformants were inoculated in 10 ml TY-medium containing 10 mg/ml Kanamycin. After 1 day of incubation at 37°C, 250rpm, 50 ml supernatant was removed. The endoglucanase activity was identified by adding 50 ml supernatant to holes punctured in the agar of LB agar plates containing 0.1% AZCL HE-cellulose.

After 16 hours incubation at 37°C blue halos surrounding holes indicated expression of the endoglucanase in *Bacillus subtilis*.

30 EXAMPLE 9

Assay for selecting CBDs

35 Preparation of phosphoric acid swollen cellulose (PASC):

5 g Avicel is moistened with water and added 150 ml ice cold 85 % phosphoric acid and is weakly stirred on an icebath for 1 hour. Then 500 ml cold acetone is added while stirring.

The swollen Avicel (PASC) is filtered on a glass-filter funnel and washed 3 times with 100 ml ice cold acetone and subsequently 2 times with 500 ml water. The PASC is then suspended in 500 ml water and blended to homogeneity using an Ultra Thorax homogenizer. The PASC is stored cold.

CBD-binding to phosphoric acid swollen cellulose (PASC) - selection of CBDs:

400 ml 10 mg/ml PASC (prepared as described above and washed with 50 mM sodium phosphate, pH 7) in 50 mM sodium phosphate, pH 7 in Eppendorf tubes was mixed with 400 ml of cellulose binding domain (Cel5A CBD or MB206 double CBD) diluted in 50 mM sodium phosphate, pH 7. The concentration of CBD was varied e.g. from 0 mM to around 8 mM for Cel5A CBD. A control series was included without PASC. The samples were incubated for 1 hour at room temperature before centrifuging the samples for 4 minutes at 14000 g. 500 µl of the supernatant was diluted into 2 ml water. The amount of CBD present in the supernatant (free CBD) was then measured by tryptophan fluorescence spectroscopy on the Perkin-Elmer LS50 luminescence spectrometer (excitation at 280 nm and emission at 340 nm) using the fluorescence intensity of the samples without PASC addition as a reference (standard curve). The amount of bound CBD was then calculated as: total CBD (without PASC addition) - free cbd. Thus, a binding isotherm was obtained by plotting the amount of bound CBD per g of PASC as a function of free CBD in solution in mM as shown in Figure 1 and Figure 2. The data could be fitted using a simple Langmuir binding model (Bothwell et al., 1995): $E(\text{bound}) = (A_{\text{max}} * E(\text{free})) / (K_d + E(\text{free}))$, where $E(\text{bound})$ is the amount of bound CBD in mmol/g PASC and $E(\text{free})$ is the amount of free CBD in mM. A_{max} is the maximum amount of CBD that can be bound to PASC and K_d is the equilibrium constant for the equilibrium $E(\text{bound}) \rightleftharpoons E(\text{free})$. Thus, the lower the K_d (desorption constant) the stronger the binding. These constants are obtained after fitting the data to the model using algorithms in GraphPad Prism. Desorption constants found for Cel5A CBD and MB206 double CBD are 0.42 and 0.76 mM respectively (cf. figure 1 and figure 2).

CBDs of the present invention show desorption constants below 1 mM more preferably below 0.1 mM and most preferably below 10 mM.

LITERATURE LIST

- Bothwell, M.K. and Walker, L.P. (1995) Bioresource Technology
5 53:21-29
- Kraulis P., G.M. Clore, M. Nilges, T.A. Jones, G. Pettersson,
J. Knowles and A.M. Gronenborn, 1989, "Determination of the
three-dimensional structure of the C terminal domain of cello-
10 biohydrolase I from *Trichoderma reesei*. A study using nuclear
magnetic resonance and hybrid distance geometry-dynamical simu-
lated annealing" in Biochemistry 28:7241-7257.
- Ong E., N.R. Gilkes, R.C. Miller and D.G. Kilburn, 1993, "The
15 cellulose-binding domain (cbdcex) of an exoglucanase from *Cel-
lulomonas fimi* - production in *Escherichia coli* and characteri-
zation of the polypeptide" in Biotechnology and Bioengineering.
42:401-409.
- 20 Linder M., I. Salovuori, L. Ruohonen and T.T. Teeri, 1996,
"Characterization of a double cellulose-binding domain -
synergistic high-affinity binding to crystalline cellulose" in
Journal of Biological Chemistry 271:21268-21272.
- 25 Peter Tomme et al. "Cellulose-Binding Domains: Classification
and Properties" in "Enzymatic Degradation of Insoluble Carbohy-
drates", John N. Saddler and Michael H. Penner (Eds.), ACS Sym-
posium Series, No. 618, 1996.
- 30 Hockney, R.C. (1994) TIBTECH, vol.12, p.456-463.
- Emmanuel Brun et al. (1995).

Eur. J. Biochem 231, 142-148.
- 35 N.R. Gilkes et al. (1991) Eur. J. Biochem, 202:367-377.

Bertus van den Berg et al., (1993), Introduction of disulfide bonds into *Bacillus subtilis* neutral protease. Protein Engineering, vol.6 no.5, p. 521-527.

- 5 Eds. A.L. Sonenshein, J.A. Hoch and Richard Losick (1993) *Bacillus subtilis* and other Gram-Positive Bacteria, American Society for microbiology, p.939 and p. 618.

- 10 Andreas Cramer et al. (1996) Improved Green Fluorescent Protein by molecular evolution using DNA shuffling, Nature Biotechnology, vol 14, p. 315-319.

Andrew B. Cubitt et al. (1995) Understanding, improving and using fluorescent proteins, TIBS, vol 20, p448-455.

- 15 Diderichsen, B., Wedsted, U., Hedegaard, L., Jensen, B. R., Sjøholm, C. (1990) Cloning of aldB, which encodes alpha-acetolactate decarboxylase, an exoenzyme from *Bacillus brevis*. J. Bacteriol., 172, 4315-4321.

- 20 Stahl, M.L. and E. Ferrari (1984) Replacement of the *Bacillus subtilis* subtilisin structural gene with an In vitro-derived deletion mutation. J. Bacteriol. 158:411-418.

- 25 Yang, M.Y. et al (1984) Cloning of the neutral protease gene of *Bacillus subtilis* and the use of the cloned gene to create an in vitro-derived deletion mutation. J. Bacteriol. 160:16-21.

- 30 S. Jørgensen et al. (1991) Journal of Bacteriology, vol. 173, No., p-559-567.

P.L. Jørgensen, C.K. Hansen, G.B. Poulsen and B. Diderichsen (1990) In vivo genetic engineering: homologues recombination as a tool for plasmid construction, Gene, 96, p37-41.

- 35 Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995

Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY.

Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological
5 Methods for Bacillus". John Wiley and Sons, 1990.

Pitcher, D. G., Saunders, N. A., Owen, R. J. (1989). Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl. Microbiol., 8, 151-156).

10

Devereux et al.

Dalbøge, H. and H.P. Heldt Hansen. 1994. A novel method for efficient expression cloning of fungal enzyme genes, Molecular &
15 General Genetics. 243:253-260.

Higuchi et al. (1988) NAR 16:7351-7367.

Gryczan, T.J. et al. (1978) Journal of Bacteriology, 134,
20 p.318-329.

Tomme P., R.A. Warren, R.C. Miller, Jr., D.G. Kilburn and N.R. Gilkes. 1995. Cellulose-Binding Domains: Classification and Properties. In: Saddler J.N. and M.H. Penner, eds. Enzymatic
25 Degradation of Insoluble Carbohydrates. Washington, DC, American Chemical Society. page 142-161.

Yasbin, R.E., Wilson, G.A. and Young, F.E. (1975) Transformation and transfection in lysogenic strains of *Bacillus subtilis* : evidence for selective induction of prophage in competent cells. J.
30 Bacteriol, 121:296-304.

CLAIMS

1. A *Bacillus* host transformed with a vector comprising a DNA sequence encoding for a cellulose binding domain (CBD) and capable of expressing said sequence, the expressed polypeptide consisting essentially of one or more non-catalytical domains.
2. The host according to claim 1, wherein the DNA sequence is of another origin than *Bacillus ssp*.
3. The host according to claim 1 or 2 which is capable of expressing the cellulose binding domain as a single polypeptide domain.
4. The host according to any of the claims 1-3, wherein the cellulose binding domain has a molecular weight in the range of from 4 kD to 35 kD.
5. The host according to claim 4, wherein the cellulose binding domain has a molecular weight not higher than 30 kD, preferably not higher than 28 kD, more preferably not higher than 25 kD.
6. The host according to any of the claims 1-5, wherein the vector comprises a DNA sequence encoding for a single cellulose binding domain.
7. The host according to any of the claims 1-5, wherein the vector comprises a DNA sequence encoding for a dimeric or a trimeric cellulose binding domain.
8. The host according to any of the claims 1-5, wherein the vector comprises a DNA sequence encoding for a cellulose binding domain which is linked to at least one other non-catalytically active domain.
9. The host according to any of the claims 1-8, wherein the cellulose binding domain is obtainable from a microorganism or from a plant, preferably a bacterium or a fungus.

10. The host according to claim 9, wherein the bacterium is selected from the group consisting of the genera *Butyrivibrio*, *Cellulomonas*, *Clostridium*, *Microbispora*, *Micromonospora*, *Pseudomonas*, *Streptomyces*, *Thermomonospora*, *Bacillus*, *Caldocellum*,
5 *Erwinia*, *Myxococcus*, *Cellvibrio*, *Thermoanaerobacterium*, and *Thermotoga*.
11. The host according to claim 9, wherein the fungus is selected from the group consisting of the genera *Agaricus*, *Dic-
10 tyostelium*, *Fusarium*, *Humicola*, *Neocallimastix*, *Neurospora*, *Limulus*, *Penicillium*, *Phanerochaete*, and *Trichoderma*.
12. The *Bacillus* host according to any of the claims 1-11 which
15 is neutralophilic, alkalophilic, mesophilic or thermophilic.
13. The *Bacillus* host according to claim 12 which is selected from the group consisting of the species *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, and *Bacillus amyloliquefaciens*.
20
14. The host according to any of the claims 1-13, wherein the vector is integrated into the genome of the untransformed host.
- 25 15. The host according to any of the claims 1-14, wherein the vector is present as an expression plasmid.
16. The host according to any of the claims 1-15, wherein the vector has been amplified on the genome or the expression plasmid is a multicopy plasmid.
30
17. A *Bacillus* expression vector which carries an inserted DNA sequence encoding for a cellulose binding domain.
- 35 18. The vector according to claim 17 in which the expression cassette comprises regulatory regions from a *Bacillus* sp.
19. The vector according to claim 18, wherein the *Bacillus* sp. regulatory regions are endogeneous to the host.

20. A method for producing a cellulose binding domain polypeptide in a *Bacillus* host cell, the method comprising the steps of:

- 5 - growing under conditions to overproduce cellulose binding domain in a nutrient medium *Bacillus* host cells which have been transformed with an expression cassette which includes, as operably joined components,
 - a) a transcriptional and translational initiation regulatory
 - 10 region,
 - b) a DNA sequence encoding the cellulose binding domain polypeptide,
 - c) a transcriptional and translational termination regulatory region, wherein the regulatory regions are functional in the
 - 15 host, and
 - d) a selection marker gene for selecting transformed host cells; and
- recovering the cellulose binding domain polypeptide.

20 21. The method according to claim 20 wherein the produced cellulose binding domain polypeptide has a molecular weight in the range of from 4 kD to 35 kD.

22. A method for optimization of CBD expression in a *Bacillus*
25 host, the method comprising the steps of:

- a. expression in the host of a CBD fused to a reporter molecule;
- b. monitoring the concentration of expressed CBD in the supernatant of the fermented host by measuring the intrinsic property or properties of the reporter molecule.

30

23. The method according to claim 22, wherein the reporter molecule is a Green Fluorescent Protein, and the intrinsic property is fluorescence emission.

35 24. A polypeptide hybriide consisting essentially of one or more cellulose binding domain(s) fused to a green flourescent protein.

25. A method of producing the hybride according to claim 24,
wherein the hybride is expressed in a *Bacillus* host, growing
the transformed host under conditions whereby the transformed
5 culture is substantially free of untransformed cells; incubat-
ing the transformed culture in a nutrient medium, whereby the
hybride is overproduced; and recovering the hybride.

1/2




Fig. 1

2/2




Fig. 2

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>23</u> , lines <u>27-28</u> .	
B. IDENTIFICATION OF DEPOSIT <div style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></div>	
Name of depositary institution NATIONAL COLLECTIONS OF INDUSTRIAL & MARINE BACTERIA LTD.	
Address of depositary institution (including postal code and country) 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland	
Date of deposit 3 March 1992	Accession Number 40482
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). As far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p align="center">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; height: 80px; margin-top: 5px;"> Authorized officer </div>	<p align="center">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input checked="" type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> 06 February 1998 (06.02.98) </div> <div style="border: 1px solid black; height: 80px; margin-top: 5px;"> Authorized officer Ting Zhao </div>
--	---

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00477

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 1/21, C12N 15/75, C12P 21/02, C12N 9/42 // (C12N 1/21, C12R1:107)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, MEDLINE, DBA, BIOSIS, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9613524 A1 (YEDA RESEARCH AND DEVELOPMENT CO.LTD.), 9 May 1996 (09.05.96), claim 30 --	1-25
X	WO 9110732 A1 (NOVO NORDISK A/S), 25 July 1991 (25.07.91), page 9, line 7 - line 13, example 5	17-19
A	--	1-16,20-25
X	US 5536655 A (STEVEN R. THOMAS ET AL), 16 July 1996 (16.07.96), column 5, line 26 - column 6, line 52	17-19
A	--	1-16,20-25

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 February 1998

Date of mailing of the international search report

19-02-1998

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson
Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00477

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9117244 A1 (NOVO NORDISK A/S), 14 November 1991 (14.11.91), page 10, line 24 - page 11, line 11	17-19
A	----- -----	1-16, 20-25

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/02/98

International application No.

PCT/DK 97/00477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9613524 A1	09/05/96	AU 4011495 A IL 111415 D IL 115774 D	23/05/96 00/00/00 00/00/00
WO 9110732 A1	25/07/91	AT 124451 T AU 7189491 A CA 2074084 A DE 69110864 D,T DK 16490 D EP 0510091 A,B ES 2075428 T JP 5503424 T	15/07/95 05/08/91 20/07/91 28/03/96 00/00/00 28/10/92 01/10/95 10/06/93
US 5536655 A	16/07/96	AU 682125 B AU 3098595 A EP 0771321 A WO 9602551 A US 5366884 A US 5432075 A AU 3594193 A EP 0577823 A US 5275944 A WO 9315186 A AU 6420290 A EP 0494207 A JP 5500752 T US 5110735 A WO 9105039 A	18/09/97 16/02/96 07/05/97 01/02/96 22/11/94 11/07/95 01/09/93 12/01/94 04/01/94 05/08/93 28/04/91 15/07/92 18/02/93 05/05/92 18/04/91
WO 9117244 A1	14/11/91	AT 150788 T AU 652153 B AU 7791091 A DE 69125371 D,T DK 115890 D EP 0531315 A,B SE 0531315 T3 ES 2100229 T US 5457046 A US 5686593 A	15/04/97 18/08/94 27/11/91 14/08/97 00/00/00 17/03/93 16/06/97 10/10/95 11/11/97

Form PCT/ISA/210 (patent family annex) (July 1992)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 15/75, C12P 21/02, C12N 9/42 // (C12N 1/21, C12R 1:107)		A1	(11) International Publication Number: WO 98/18905 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/DK97/00477 (22) International Filing Date: 28 October 1997 (28.10.97) (30) Priority Data: 1192/96 28 October 1996 (28.10.96) DK 1426/96 13 December 1996 (13.12.96) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): BJØRNVAD, Mads, Eskelund [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). SCHÜLEIN, Martin [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). JØRGENSEN, Per, Linå [DK/DK]; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13^{bis} separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 6 February 1998 (06.02.98) (88) Date of publication of the revised version of the international search report: 11 September 1998 (11.09.98)	
(54) Title: EXTRACELLULAR EXPRESSION OF CELLULOSE BINDING DOMAINS (CBD) USING BACILLUS			
(57) Abstract <p>A <i>Bacillus</i> host transformed with a vector comprising a DNA sequence encoding for a cellulose binding domain (CBD) and capable of expressing said sequence, the expressed polypeptide protein consisting essentially of one or more non-catalytical domains; the cellulose binding domain having a molecular weight in the range of from 4 kD to 35 kD and being obtainable from a microorganism or from a plant, preferably from a bacterium or a fungus; the <i>Bacillus</i> host e.g. being one of the species <i>Bacillus subtilis</i>, <i>Bacillus licheniformis</i>, <i>Bacillus megaterium</i>, <i>Bacillus stearothermophilus</i> and <i>Bacillus amyloliquefaciens</i>; and a <i>Bacillus</i> expression vector carrying an inserted DNA sequence encoding for a cellulose binding domain; and a method for producing a cellulose binding domain polypeptide in a <i>Bacillus</i> host cell.</p>			

*(Referred to in PCT Gazette No. 36/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00477

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 1/21, C12N 15/75, C12P 21/02, C12N 9/42 // (C12N 1/21, C12R1:07)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, MEDLINE, DBA, BIOSIS, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9613524 A1 (YEDA RESEARCH AND DEVELOPMENT CO.LTD.), 9 May 1996 (09.05.96), claim 30 --	1-25
X	WO 9110732 A1 (NOVO NORDISK A/S), 25 July 1991 (25.07.91), page 9, line 7 - line 13, example 5	17-19
A	--	1-16,20-25
X	US 5536655 A (STEVEN R. THOMAS ET AL), 16 July 1996 (16.07.96), column 5, line 26 - column 6, line 52	17-19
A	--	1-16,20-25

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

31 July 1998

Date of mailing of the international search report

03-08-1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00477

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9117244 A1 (NOVO NORDISK A/S), 14 November 1991 (14.11.91), page 10, line 24 - page 11, line 11	17-19
A	----- -----	1-16, 20-25

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/06/98

International application No.
PCT/DK 97/00477

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9613524	A1	09/05/96	AU	4011495 A	23/05/96
				IL	111415 D	00/00/00
				IL	115774 D	00/00/00

WO	9110732	A1	25/07/91	AT	124451 T	15/07/95
				AU	7189491 A	05/08/91
				CA	2074084 A	20/07/91
				DE	69110864 D,T	28/03/96
				DK	16490 D	00/00/00
				DK	510091 T	27/11/95
				EP	0510091 A,B	28/10/92
				ES	2075428 T	01/10/95
				FI	923275 A	17/07/92
				JP	5503424 T	10/06/93

US	5536655	A	16/07/96	AU	682125 B	18/09/97
				AU	3098595 A	16/02/96
				EP	0771321 A	07/05/97
				US	5712142 A	27/01/98
				WO	9602551 A	01/02/96
				US	5366884 A	22/11/94
				US	5432075 A	11/07/95
				AU	3594193 A	01/09/93
				EP	0577823 A	12/01/94
				US	5275944 A	04/01/94
				WO	9315186 A	05/08/93
				AU	6420290 A	28/04/91
				EP	0494207 A	15/07/92
				JP	5500752 T	18/02/93
				US	5110735 A	05/05/92
				WO	9105039 A	18/04/91

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/06/98

International application No.

PCT/DK 97/00477

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9117244 A1	14/11/91	AT 150788 T	15/04/97
		AU 652153 B	18/08/94
		AU 7791091 A	27/11/91
		DE 69125371 D,T	14/08/97
		DK 115890 D	00/00/00
		DK 531315 T	22/09/97
		EP 0531315 A,B	17/03/93
		SE 0531315 T3	
		ES 2100229 T	16/06/97
		FI 925080 A	09/11/92
		US 5457046 A	10/10/95
		US 5686593 A	11/11/97
		US 5763254 A	09/06/98
<hr/>			

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.